XBiotech Inc. - Common Shares, no par value (XBIT)

Historical Holders from Q2 2015 to Q3 2025

Symbol: XBIT on Nasdaq
Type / Class: Equity / Common Shares, no par value
Shares outstanding: 33,289,095
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 2,935,115
Holdings value: $7,807,395
% of all portfolios: 0%
Number of holders: 45
Number of buys: 15
Number of sells: -29
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of XBiotech Inc. - Common Shares, no par value (XBIT)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
SIMARD JOHN	19.9%		$19,476,118		6,624,530		John Simard	31 Dec 2024
MCKENZIE W THORPE	9.71%		$9,799,030		2,987,509		W. Thorpe McKenzie	31 Dec 2024

Institutional Holders of XBiotech Inc. - Common Shares, no par value (XBIT)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	2,935,115	$7,807,395	-$1,319,023			$2.66	45
2025 Q2	3,415,938	$10,142,998	-$3,226,983			$2.97	51
2025 Q1	4,477,932	$14,507,144	-$783,251	$0	$0	$3.24	54
2024 Q4	4,716,023	$18,630,129	-$1,607,590	$50,560	$790	$3.95	52
2024 Q3	4,851,370	$37,501,383	+$1,645,507	$0	$0	$7.73	49
2024 Q2	4,516,257	$23,226,349	+$2,719,004	$23,644	$29,812	$5.14	45
2024 Q1	3,994,151	$32,477,639	+$4,760,265	$13,821	$51,219	$8.13	44
2023 Q4	3,446,049	$13,790,459	+$111,471	$800	$3,200	$4	37
2023 Q3	3,395,054	$13,985,979	-$309,786	$22,248	$412	$4.12	37
2023 Q2	3,480,241	$20,672,616	+$5,847,574	$30,888	$11,286	$5.94	37
2023 Q1	2,492,253	$8,596,457	-$920,920	$37,260	$0	$3.45	33
2022 Q4	2,756,601	$9,673,374	-$1,051,732		$6,669	$3.51	37
2022 Q3	3,051,376	$11,045,334	-$1,558,767			$3.62	40
2022 Q2	3,360,539	$18,915,124	-$4,739,956			$5.63	48
2022 Q1	3,963,565	$34,247,851	-$2,001,192		$0	$8.64	55
2021 Q4	3,965,072	$44,131,901	-$1,897,441	$674,000	$227,000	$11.13	51
2021 Q3	4,343,993	$56,286,719	+$4,058,859	$399,000	$0	$12.95	64
2021 Q2	4,022,892	$66,543,749	-$4,425,895	$608,000	$267,000	$16.56	55
2021 Q1	4,286,860	$73,476,400	+$5,856,017	$1,035,000	$0	$17.17	62
2020 Q4	3,920,951	$61,377,705	+$427,571	$1,430,000	$249,000	$15.65	61
2020 Q3	3,868,696	$73,847,185	-$5,828,868	$1,416,000	$787,000	$19.09	65
2020 Q2	4,270,964	$58,556,257	-$399,448	$1,215,000	$188,000	$13.71	60
2020 Q1	4,363,780	$46,347,234	-$15,868,651	$1,080,000	$267,000	$10.62	56
2019 Q4	5,467,627	$102,055,050	+$15,755,685	$648,000		$18.67	57
2019 Q3	4,900,401	$51,286,090	+$5,925,931	$667,000		$10.46	43
2019 Q2	4,410,025	$33,425,690	+$13,189,492	$590,000	$0	$7.58	42
2019 Q1	2,545,792	$28,051,606	+$16,117,958	$942,000	$353,000	$11.02	36
2018 Q4	1,108,524	$5,632,279	-$1,834,365	$188,000		$5.08	21
2018 Q3	1,524,110	$4,844,175	-$1,069,158	$103,000	$0	$3.18	20
2018 Q2	1,777,227	$7,961,246	-$6,157,610	$145,000	$118,000	$4.48	28
2018 Q1	3,165,524	$16,935,156	-$558,547	$139,000	$142,000	$5.35	41
2017 Q4	3,293,461	$12,972,785	-$2,266,867	$356,000	$56,000	$3.94	41
2017 Q3	3,883,034	$16,963,807	+$659,798	$603,000	$64,000	$4.37	44
2017 Q2	3,711,486	$17,439,623	-$1,951,584	$627,000	$475,000	$4.7	41
2017 Q1	3,597,093	$59,310,105	+$24,181,685	$3,091,000	$1,632,000	$16.48	47
2016 Q4	3,461,617	$35,024,345	+$1,328,410	$647,000	$277,000	$10.12	47
2016 Q3	3,292,636	$44,309,081	+$5,759,072	$700,000		$13.46	47
2016 Q2	2,793,021	$58,425,421	+$31,398,661			$20.92	46
2016 Q1	1,321,183	$12,486,000	-$435,598			$9.45	32
2015 Q4	1,347,068	$14,634,326	+$5,581,826			$10.87	34
2015 Q3	763,606	$11,426,133	+$2,304,096			$14.94	30
2015 Q2	570,575	$10,259,741	+$10,259,743			$18.09	30